#AtrialFibrillation #guidelines 2024 at #ESCCongress academic.oup.com/eurheartj/adva… New recommendations aligned with #CARE 👇🏽 #Anticoagulation recommended in ChadVasc2 or anyone with HCM / Amyloid -> re-evaluate risk Strong focus on managing #comorbidities and symptoms!

2024 #ESCGuidelines for the management of #afib developed in collaboration with the European Association for Cardio-Thoracic Surgery EACTS : Developed by the task force for the management of atrial fibrillation of European Society of Cardiology, with the special contribution of the European Heart

#BetaBlocker Use after Myocardial Infarction‼️ No differences between BB interruption vs. continuation‼️ #ESC24 #ESCCongress #NEJM

Historic day today for cardiology! IVUS or OCT as Class I recommendation in PCI of complex lesions. Congratulations to #ESCCongress2024 for leading the way in positioning IVI in this category. European Society of Cardiology #CardioOCT

#ESCCongress #ESCHotline #LBCT HELIOS-B: Vitrisiran I Improved outcomes 🆚 placebo in ATTR Improved QoL as well European Society of Cardiology

The overview of the European Society of Cardiology 2024 ESC Guidelines for the Management of Elevated Blood Pressure & #Hypertension was earlier today but join us in London room at 1345 for the detailed deep dive! Congratulations to the TaskForce led by Co-Chairs John William McEvoy The Touyz Lab The

Debate: Is TTVI Hot?? All agree that it’s 🔥! Philipp Lurz Marianna Adamo European Society of Cardiology #ESCCongress2024 #ESC2024

Happening now European Society of Cardiology 2024 ESC Guidelines for Mgt of Elevated #BloodPressure & #Hypertension Prof The Touyz Lab 🔦 the new #HTN #GLs include 57 new recommendations ♥️ includes sex & gender are integral throughout the document & not a “special group” or section

Second T-TEER randomized trial: Tri-FR! Presented at #ESC2024 #ESCCongress2024 by Donal showing similar TRILUMINATE results: primary 1Yr endpoint driven by QoL but numerically lower mortality and HFH. Longer FU needed. European Society of Cardiology News European Society of Cardiology

OCEANIC-AF stopped early due to inferiority of factor XI inhibitor asundexian vs. apixaban in AFib. Download slides presented at #ESCCongress here: clinicaltrialresults.org/wp-content/upl…

Glad to see the presentation on the COASTLINE study. Congratulations to Prof von Birgelen, dr van Vliet and the study team. #ESC2024

Congratulations to the study team.

PROFID EHRA_ESC TV Recording with Valentina Kutyifa (Rochester), Nikolaos Dagres (Berlin) & yours truly. PROFID #ESCCongress RCT to test the effectiveness of primary prevention ICD in #heartfailure after #heartattack Look of for the TV session.

European Cardiology Congress in London 🫀🇬🇧 #ESC2024 More than 25,000 cardiologists from all over the world in a wonderful city! Always an honor and a pleasure to participate with lectures and discussions in packed classrooms bearing the name of the city and the group I work

Get the American perspective on the new #ESCGuidelines presented at #ESCCongress, particularly on the guidelines on #ChronicCoronarySyndromes Brought to you by Dr Roxana Mehran and C. Michael Gibson MD Get the new guidelines full documents on the European Society of Cardiology website 👉

🚨FINEARTS-HF trial, finerenone reduced HF events and cardiovascular death in patients with HFmrEF/HFpEF🚨 #ESCCongress #FINEARTS #HFpEF #LBCT #ESCHotline 📎 nejm.org/doi/abs/10.105… 📍46%💃🏻 📍16% Asian 📍mean age 72y 📍not on top of SGLT2i 📍v symptomatic population

Picture worth 1000 words

Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease bit.ly/4eLbOAQ

Beyond the Data: my TCTMD video for the SENIOR-RITA Trial ➡️ tctmd.com/videos/beyond-… Thank you to Prof Rob Storey who had to step in at short notice for Professor Vijay Kunadian

Knowing about the health of our decision makers and figureheads treads a fine line between privacy and the public right to know, or to question it. Charlotte Lytton writes on the health of a leader—and when it has been questioned bmj.com/content/386/bm…